EDGAR·FLOW

Apimeds Pharmaceuticals US, Inc. — Form 8-K

Filed November 20, 2026 · analyzed by the 8-K Agent
8-K — Neutral significance 72/100
What the filing says
On November 12, 2026, Apimeds amended its August 19, 2026 Apitox rights assignment agreement with FreeT Inc. (South Korea). Consideration structure: (1) Initial Shares: 350,000 common shares (par $0.001), due by December 1, 2026; (2) Additional Consideration: contingent on third-party valuation — if final valuation exceeds the initial share value, Apimeds pays the excess in cash or stock within 30 days; if valuation equals or falls below initial value, no additional payment due. Valuation process: independent appraiser jointly appointed within 60 days, delivers report within 60 days thereafter. Shares are unregistered, restricted securities under Rule 144.
Why this rating

350k shares ≈ 4.5% dilution (material for $7.8M company); contingent liability unknown until valuation. Pharma asset acquisition is strategic but valuation outcome uncertain. Moderate near-term stock risk.

Price action (we called it neutral)
before filing · preread
$1.65
at our read
pending
+10 min
pending
+30 min
pending
+1 hr
pending
+4 hrs
pending

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ APUS · stock on Yahoo Finance ↗

See more from November 20, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.